-
The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling sales.
-
The lawsuits add to a web of patent disputes between biotech companies over technology used in the coronavirus shots, including a case brought last year in Massachusetts by Moderna against Pfizer and its partner BioNTech.
-
The WHO in its latest Strategic Advisory Group of Experts on Immunization (SAGE) has revised the roadmap for prioritising use of COVID-19 vaccines. Here’s all you need to know
-
Moderna and Merck plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types.
-
African countries struggled early in the pandemic to secure COVID vaccines as rich countries hoarded doses. But many are now well-supplied with shots and are instead having trouble administering them, either because of hesitancy or logistics.
-
Switzerland has fully vaccinated nearly 70 percent of its population of 8.7 million.
-
Moderna Inc. said it’s suing Pfizer Inc. and BioNTech SE, claiming the technology in the partners’ Covid-19 shot infringes on its patents, a move that sets the stage for a massive legal clash between the three vaccine titans.
-
The UK medicines regulator (MHRA) gave the so-called bivalent vaccine made by U.S. drug company Moderna conditional approval as a booster for adults on Monday.
-
On Wednesday, a panel of FDA advisers unanimously recommended that the agency approve COVID-19 vaccinations from Moderna Inc and Pfizer Inc/BioNTech SE for millions of youngsters in the United States.
-
The US Centers for Disease Control and Prevention stated on Tuesday that Moderna's (MRNA.O) COVID-19 vaccine may cause more cardiac inflammation in some age groups than Pfizer-(PFE.N) BioNTech's injection, citing recent research.
-
Moderna Inc said on Wednesday that its COVID-19 vaccine booster, which targets both the original coronavirus strain and Omicron, elicited a stronger immune response against the variant than the company's previous vaccine.
-
The study of 5,893 participants between May and November last year showed that 22.4% of women developed delayed skin reactions after the first shot, compared to 5.1% of men.
-
Moderna Inc. Chief Executive Officer Stephane Bancel said he plans to donate the bulk of his family wealth, focusing his philanthropy on issues such as health care and ghobal food security.
-
Leaders at the World Economic Forum on Monday said everyone else needs to follow the Indian model to ensure vaccine equity and wider inoculation.
-
The findings, published in The Lancet Infectious Disease journal, show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received Pfizer as a third dose.
-
Moderna, like rival Pfizer, maintained its full-year sales forecast for the vaccine at $21 billion.
-
Children under six are the only age group that has yet to gain access to a COVID-19 vaccine in the United States and in most countries.
-
The company’s findings, published in a paper without being evaluated by outside scientists, offer hope that the nation will have a better vaccine by the fall, when the coronavirus is considered likely to reemerge in force.
-
The Food and Drug Administration authorized extra Pfizer or Moderna shots for anyone 50 or older and for some younger people with severely weakened immune systems. It’s an effort to get ahead of a possible next coronavirus surge.
-
Moderna said that in the coming weeks it would ask regulators in the US and Europe to authorize two small-dose shots for youngsters under 6. The company also is seeking to have larger doses cleared for older children and teens in the US.
-
Moderna, without specifically commenting on the effectiveness of a fourth shot, said its submission was partly based on data recently published in the United States and Israel following the emergence of the Omicron variant.
-
The jab, developed by US-based pharmaceutical company Moderna, has already been approved for adults and children aged 12 and above.
-
Dr Paul was heading the initiative of negotiating with these three vaccine makers on behalf of the central government. Despite the demands, he said, the government tried to find more ways for these companies to bring the vaccines to India.
-
Last month Moderna began clinical trials for a booster dose specifically designed to target Omicron but initial results from studies in monkeys show the Omicron-specific shot may not offer stronger protection than a new dose of the existing vaccine.
-
Nearly 75 million people have already received Moderna's two-dose vaccine in the United States, according to data from the U.S. Centers for Disease Control and Prevention.
